Clinical Trial

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.
Protocol Amendment History 2 changes
notable Enrollment increased: 72 -> 102 participants 2026-05-19
minor Trial arms changed: 3 -> 4 2026-05-19
Trial Details
NCT Number NCT06769113
Lead Sponsor Shanghai Henlius Biotech
Conditions Esophageal Cancer
Enrollment 102 participants
Start Date 2025-01-26
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-18